ASEP Medical Holdings Inc | November 25, 2022
Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November 24, 2032.
ABOUT ASEP MEDICAL HOLDINGS INC
Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The semester test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections anti-inflammatories, anti-infective immune modulators, and vaccine adjuvants.
HEALTH TECHNOLOGY,MEDICAL DEVICES
Predictive Health Solutions | December 06, 2022
With the Predictive Health Solutions Patient No-Show Predictor, providers now have a new tool in combatting patient no-shows. By leveraging the power of predictive analytics, the PHS Patient No-Show Predictor can also help reduce patient backlogs and long waitlists, improve operational efficiencies, promote better patient health outcomes, increase potential revenues, enhance patient care, and minimize caregiver burnout.
Powered by SAS analytics software and co-developed by Pinnacle Solutions, the solution seamlessly integrates cutting edge technology into pre-existing daily operations, making it easy for healthcare staff to use. The solution identifies high-risk patients as well as potential key risk factors impacting a patient's ability to attend their appointment, such as weather, social determinants of health, or many other factors. Using the information provided, staff can quickly make informed decisions regarding intervention strategies that directly impact the patient's likelihood of attending their appointment and receiving the care they need. For example, staff may choose to offer alternative options to those with unreliable transportation or suggest afternoon appointments for those whose morning commute would be impacted by traffic delays. Teams may also choose to use the intelligence gathered to customize individual reminder protocols to maximize the impact and value of those existing tools. Data gathered can also be leveraged for strategic overbooking, as opposed to, for example, blindly scheduling same-day appointments.
Patient no-shows cost the US and Canadian healthcare systems more than $150 billion annually, and those numbers are likely higher as a result of the COVID-19 pandemic. The ensuing funding shortages not only impact the bottom line, but also directly affect healthcare systems' ability to provide the desired level of care, which in many cases creating even greater accessibility and availability issues. For instance, revenue lost as a result of no-shows could be used to fund additional medical staff or provide the latest medical technologies and therapy sessions for patients in need.
Predictive Health Solutions is a joint venture with Pinnacle Solutions, Inc. and the Center For Discovery, Innovation and Development an affiliate member of RWJBarnabas Health and a member of Children's Miracle Network Hospitals. PHS was established to improve access to healthcare, improve diagnostic algorithms, and enhance patient outcomes. PHS uses patient data and external sources to develop solutions that address healthcare needs better. Using machine learning algorithms and artificial intelligence, PHS helps organizations create optimal health for their communities.
FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS
Juno Medical | December 12, 2022
Juno Medical, the modern doctor's office that's designed for the 99%, today announced $12 million in Series A funding co-led by Julian Eison, Managing Partner at NEXT VENTURES, and Serena Williams, Managing Partner at Serena Ventures. Juno’s comprehensive tech-enabled healthcare model is designed to meet the everyday healthcare needs of "the 99%,” with a specific focus on revitalizing neighborhoods across the United States and delivering a beautiful environment, transparent pricing, and exceptional care. The funding will support Juno’s continued development of its technology platform and expansion into new markets, including Atlanta, Georgia, Tulsa, Oklahoma, and Los Angeles, California.
Other notable participants include Vast Ventures, which led Juno’s seed round, Empire State Development’s New York Ventures, TXV Partners, Genius Guild, Gaingels, and previous investors Atento Capital and Humbition.
Juno’s team has unmatched healthcare, technology, and business expertise. Juno Founder and CEO Dr. Akili Hinson’s background spans medicine and business. He is a physician by training and former McKinsey & Company consultant with expertise in payment innovation, value-based care delivery, and digital transformation. Juno’s medical leadership team includes Chief Health Officer Dr. Aarti Agarwal, an internist and epidemiologist with expertise in global health and value-based care, as well as Juno’s two founding physicians, Dr. Shante Hinson, a rheumatologist and preventative health expert dedicated to bridging the healthcare gap in underserved communities, and Dr. Candice Fraser, an OB/GYN with over a decade of experience as a trusted guide in women's health.
“Juno’s vision is to reimagine the future of healthcare by finally making exceptional, family-centered care accessible and affordable for the 99% all across the United States. At Juno, we’ve designed healthcare that people love by providing the highest quality care and incredible service in a beautiful environment that feels like a place to belong—all powered by modern technology. We are honored by the support of the thousands of patients who have trusted us with their care and our investors who believe in us — we could not be more excited to bring Juno to more neighborhoods and communities all across the country.”
Dr. Akili Hinson
Juno’s products and services are designed for the family’s “Chief Caregiver” by bringing the best of primary care, pediatrics, women's health, same-day care, and virtual care into one thoughtfully designed experience.
“It brings joy to my heart knowing Juno is on a mission to bring exceptional healthcare to cities and developing areas of our nation where suboptimal care, facilities, and services have been tolerated out of necessity for way too long," said Julian Eison, Managing Partner of NEXT VENTURES. “I believe Juno’s hybrid approach leveraging brick and mortar clinics paired with digital access is an enduring model that will serve as the fundamental basis to build community trust and outcomes to match. It’s an honor to have partnered with such an esteemed team, attacking one of the largest problems of our time.”
Juno accelerated the opening of its first location in the Harlem neighborhood of New York City to see patients in April 2020 when the COVID-19 pandemic devastated New York and many physician offices were closed. In addition to providing COVID testing and care to hundreds of residents, Juno continued to offer in-person preventive care during the pandemic which led to the identification of treatable cancers and previously undiagnosed chronic conditions in asymptomatic women and men — which may have been missed in the absence of the founding team’s commitment to serve.
“We are honored to partner with Juno to expand upon their inclusive, full-service healthcare home model where people from all backgrounds feel seen, heard and welcome,” said Serena Williams, Managing Partner of Serena Ventures. “There is a serious need to address equity issues in healthcare, mental health and wellness services that many communities face. Juno and its talented team have the vision, model and track record to disrupt the unacceptable status quo in healthcare.”
Juno’s approach and presence in underserved communities is part of the solution to a growing challenge of healthcare disparities that exist across the United States. A recent report from the Kaiser Family Foundation outlined race-based disparities in maternal and infant health and mortality. The markets in which Juno will expand have their own unique health care challenges. On November 1, Atlanta Medical Center closed its doors, leaving an already-strained healthcare system with one less option and exacerbating concerns about the future of safety net hospitals in the region and state. In North Tulsa, where Juno’s clinic will be located, residents have a life expectancy 13 years shorter than their neighbors in South Tulsa.
“Empire State Development’s New York Ventures exists to partner with promising startups that are working to solve the world’s most important challenges, and we are proud to support Juno Medical as they strive to provide exceptional healthcare to New Yorkers, especially in areas that are often overlooked or left behind,” said Hope Knight, President, CEO and Commissioner of Empire State Development. “Juno’s success in New York State is a road map for the future and a proven model for delivering quality, affordable healthcare for all.”
Unlike recent trends in concierge medicine and digital health, Juno’s model is designed to work with nearly all types of insurance—including commercial plans, Medicare and Medicaid—without initial barriers or exclusive membership fees. Juno is taking a different approach to meet the needs of busy households by offering additional plans that start at $20 per month per person or $50 per month per family that complement its core services with added conveniences like night and weekend appointments, savings, and unique events and experiences. Juno’s hybrid model includes both in-person options for patients and a robust e-health platform, which includes an app that allows patients to make appointments, manage care information, and keep in touch with their care team.
As part of its mission to create a healthier world, Juno will use this funding to expand into new markets and recruit the highest-caliber provider talent in Atlanta, Tulsa and Los Angeles. Juno’s new clinics will be located in the historic yet overlooked neighborhoods of East Atlanta, Greenwood (Tulsa), and Inglewood (Los Angeles). The funding will also support the continued expansion of Juno’s robust technology platform for both patients and healthcare providers—a critical component of Juno’s innovative model.
About Juno Medical
Launched in April 2020, Juno Medical is a tech-enabled healthcare service provider designed for you and yours. The company offers exceptional hospitality, modern technology, and transparent prices that won't break the bank and brings the best of adult primary care, pediatrics, women's health, and same-day care into one thoughtful and beautifully designed place.
DIGITAL HEALTHCARE, MEDICAL DEVICES
Swisslog Healthcare | December 19, 2022
Swisslog Healthcare, a leading supplier in healthcare technology solutions of both medication management and transport automation, has appointed Cory Kwarta as its CEO. Kwarta, who was appointed as CEO of the Swisslog Healthcare – TransLogic division earlier this year, is now entrusted to oversee the global organization, guiding both the company’s TransLogic® and Medication Management divisions.
“Since I started at Swisslog Healthcare, my goal has always been to help improve efficiencies in the healthcare industry. As CEO of the company, I will remain dedicated to our organization’s commitment of helping our customers and partners provide the highest quality healthcare.”
Cory Kwarta was also recently named as a member of Swisslog Healthcare’s Board of Directors. The move came as a result of Kwarta’s recent prior promotion to CEO of Swisslog Healthcare – TransLogic and his 15 years of service with the organization.
Kwarta has a bachelor’s degree in systems engineering from the United States Military Academy at West Point and a master’s degree in business administration from the University of Denver.
Swisslog Healthcare’s TransLogic division works with healthcare facilities to develop custom-designed pneumatic tube systems which automate their needs to transport materials from station to station. The Medication Management division of Swisslog Healthcare assists healthcare facilities with automating and managing the pharmaceutical workflow, including preparation, patient-specific dosing, delivery, and storage. Both divisions deliver operational cost reduction by enabling the redeployment of personnel to patient-facing activities.
About Swisslog Healthcare
Swisslog Healthcare provides integrated medication supply chain solutions to hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patient’s needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways.